KIR3DL2-targeted CAR-T cells (allogeneic)

KIR3DL2-targeted CAR-T cells (allogeneic) is an investigational, off-the-shelf chimeric antigen receptor (CAR) T-cell therapy designed for the treatment of mature T-cell lymphomas (TCL), including cutaneous T-cell lymphoma (CTCL) subtypes such as Sézary syndrome and transformed mycosis fungoides. The therapy targets KIR3DL2 (CD158k), a killer cell immunoglobulin-like receptor that is highly and specifically expressed on malignant T cells but minimally present on healthy T cells. To enable an allogeneic approach, the cells are engineered using CRISPR-Cas9 to knock out the T-cell receptor alpha constant (TRAC) and beta-2 microglobulin (β2M) genes, thereby mitigating the risk of graft-versus-host disease (GvHD) and immune rejection. Additionally, the cells are engineered to express HLA-E to enhance persistence. Preclinical data presented at EHA 2026 demonstrated robust in vitro cytotoxicity and significant in vivo tumor regression in xenograft models.

Other names

KIR3DL2-directed allogeneic CAR-T cellsKIR-3DL2-directed allogeneic CAR-T cellsKIR 3DL2-directed allogeneic CAR-T cellsallogeneic KIR3DL2-targeted CAR-T cell therapy